Maurya et al. examined the prevalence of MDR-TB due to the use of first line drug changing pattern trends within the next 4 years. Current report from Northern India show 3% (new) cases and 13% (acquired) cases. The surveillance program of drug resistant TB and the use of drug resistant testing may help with establishing standard protocol for chemotherapy and allowing for routine assessment of the program. Specimens were collected from both respiratory and non-respiratory route. The participants were male and female, all ages from urban and rural settings that had new or previously treated for pulmonary TB and extra pulmonary TB. Clinical information, family history of TB, and history of prior use of antimicrobial medications were obtained.
